Evolus, Inc. (LON:0K16)
14.58
+0.43 (3.00%)
At close: Jan 31, 2025
Evolus Employees
Evolus had 329 employees as of September 30, 2025. The number of employees increased by 7 or 2.17% compared to the same quarter last year.
Employees
329
Change
7
Growth
2.17%
Revenue / Employee
646.31K GBP
Profits / Employee
-132.42K GBP
Market Cap
203.66M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 329 | 7 | 2.17% |
| Jun 30, 2025 | 394 | 90 | 29.61% |
| Mar 31, 2025 | 372 | 93 | 33.33% |
| Dec 31, 2024 | 332 | 59 | 21.61% |
| Sep 30, 2024 | 322 | 76 | 30.89% |
| Jun 30, 2024 | 304 | 89 | 41.40% |
| Mar 31, 2024 | 279 | 55 | 24.55% |
| Dec 31, 2023 | 273 | 58 | 26.98% |
| Sep 30, 2023 | 246 | 33 | 15.49% |
| Jun 30, 2023 | 215 | 41 | 23.56% |
| Mar 31, 2023 | 224 | 50 | 28.74% |
| Dec 31, 2022 | 215 | 48 | 28.74% |
| Sep 30, 2022 | 213 | 64 | 42.95% |
| Jun 30, 2022 | 174 | 44 | 33.85% |
| Mar 31, 2022 | 174 | 68 | 64.15% |
| Dec 31, 2021 | 167 | 48 | 40.34% |
| Sep 30, 2021 | 149 | 24 | 19.20% |
| Jun 30, 2021 | 130 | 3 | 2.36% |
| Mar 31, 2021 | 106 | -114 | -51.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,000 |
| Integrated Diagnostics Holdings | 6,309 |
| Tristel | 267 |
| Diaceutics | 213 |
| Animalcare Group | 201 |
Evolus News
- 4 weeks ago - Stifel Analyst Lowers Price Target on Evolus (EOLS) to $17.00 | EOLS Stock News - GuruFocus
- 4 weeks ago - Evolus (EOLS) Achieves Sixth Year of Double-Digit Growth in 2025 - GuruFocus
- 4 weeks ago - Evolus (EOLS) Projects Strong Revenue Growth Through 2028 - GuruFocus
- 4 weeks ago - Evolus sees Q4 net revenue between $88.6M and $90.6M - Seeking Alpha
- 4 weeks ago - Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue - Business Wire
- 7 weeks ago - Needham Reiterates Hold Rating for Evolus (EOLS) | EOLS Stock News - GuruFocus
- 2 months ago - Evolus: A Difficult 2025 Means I'm Downgrading Stock To 'Hold' For 2026 - Seeking Alpha
- 2 months ago - AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings - Seeking Alpha